Skip to Content
Merck
CN
All Photos(1)

Documents

565788

Sigma-Aldrich

β-Secretase Inhibitor IV

≥98% (HPLC), solid, β-secretase inhibitor, Calbiochem®

Synonym(s):

β-Secretase Inhibitor IV, BACE Inhibitor C3

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C31H38N4O5S
CAS Number:
797035-11-1
Molecular Weight:
578.72
UNSPSC Code:
12352200
NACRES:
NA.77

product name

β-Secretase Inhibitor IV, β-Secretase Inhibitor IV, CAS 797035-11-1, is a cell-permeable inhibitor that binds to BACE-1 active site and blocks its proteolytic activity (IC₅₀ = 15 nM for human BACE-1).

Quality Level

100

Assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

white

solubility

DMSO: 100 mg/mL

shipped in

ambient

storage temp.

2-8°C

InChI

1S/C31H38N4O5S/c1-21(23-12-8-5-9-13-23)33-30(37)24-17-25(19-27(18-24)35(2)41(3,39)40)31(38)34-28(16-22-10-6-4-7-11-22)29(36)20-32-26-14-15-26/h4-13,17-19,21,26,28-29,32,36H,14-16,20H2,1-3H3,(H,33,37)(H,34,38)/t21-,28+,29-/m1/s1

InChI key

VPNIQGRFZCTBEZ-SPTGULJVSA-N

General description

A cell-permeable and potent inhibitor that binds to BACE-1 active site and blocks its proteolytic activity (IC50 = 15 nM for BACE-1, human and 29 nM for sAPP_NF in HEK293-APPNFEV cells). Displays greater selectivity over other aspartyl proteases (IC50 = 230 nM, 7.6 µM and >50 µM for BACE-2, cathepsin D, and renin, respectively).
A cell-permeable isophthalamide compound containing hydroxyethylamine motif that binds to BACE-1 active site and potently blocks its proteolytic activity (IC50 = 15 nM for BACE-1, human and 29 nM for sAPP_NF in HEK293-APPNFEV cells). Displays greater selectivity over other aspartyl proteases (IC50 = 0.23 µM, 7.6 µM and >50 µM for BACE-2, cathepsin D, and renin, respectively). Also available as a 10 mM solution in DMSO (Cat. No. 565794).

Please note that the molecular weight for this compound is batch-specific due to variable water content.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
BACE-1 human
Product does not compete with ATP.
Reversible: no
Target IC50: 15 nM for BACE-1, human and 29 nM for sAPP_NF in HEK293-APPNFEV cells

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Halima, S.B., et al. 2016. Cell Reports.14, In press.
Stachel, S.J., et al. 2004. J. Med. Chem.47, 6447.
Solubilize in DMSO (10 mg/ml), aliquot & store at -20*C; stable for 3 months.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yuji Kamikubo et al.
Frontiers in molecular neuroscience, 15, 1068990-1068990 (2023-01-24)
Alzheimer's disease (AD) is a progressive neurodegenerative brain disorder and the most common cause of dementia in the elderly. The presence of large numbers of senile plaques, neurofibrillary tangles, and cerebral atrophy is the characteristic feature of AD. Amyloid β
Christiane Volbracht et al.
Analytical biochemistry, 387(2), 208-220 (2009-05-21)
Amyloid-beta peptide (Abeta), a putatively causative agent of Alzheimer's disease (AD), is proteolytically derived from beta-amyloid precursor protein (APP). Here we describe cellular assays to detect the activity of the key protease beta-site of APP cleaving enzyme 1 (BACE1) based
Hirotaka Watanabe et al.
Methods in molecular biology (Clifton, N.J.), 2549, 209-217 (2021-05-08)
Amyloid β (Aβ) peptides are the main component of the characteristic insoluble deposits in brain parenchyma and small blood vessels in the patients afflicted with Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA). These small peptides are attributed to the
Noa Stern et al.
International journal of molecular sciences, 23(21) (2022-11-12)
Alzheimer's disease (AD) is a complex and widespread condition, still not fully understood and with no cure yet. Amyloid beta (Aβ) peptide is suspected to be a major cause of AD, and therefore, simultaneously blocking its formation and aggregation by
Helen A Rowland et al.
Neuronal signaling, 7(4), NS20230016-NS20230016 (2023-10-09)
Alzheimer's disease (AD) is characterised by the aggregation and deposition of amyloid-β (Aβ) peptides in the human brain. In age-related late-onset AD, deficient degradation and clearance, rather than enhanced production, of Aβ contributes to disease pathology. In the present study
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service